Century Therapeutics, Inc. (IPSC) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 7 Buy, 2 Hold.
The consensus price target is $3.00 (low: $2.00, high: $4.00), representing an upside of 26.6% from the current price $2.37.
Analysts estimate Earnings Per Share (EPS) of $-1.62 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.61 vs est $-1.62 (beat +0.4%). 2025: actual $-0.11 vs est $-0.18 (beat +38.9%). Analyst accuracy: 68%.
IPSC Stock — 12-Month Price Forecast
$3.00
▲ +26.58% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Century Therapeutics, Inc., the average price target is $3.00, with a high forecast of $4.00, and a low forecast of $2.00.
The average price target represents a +26.58% change from the last price of $2.37.
Highest Price Target
$4.00
Average Price Target
$3.00
Lowest Price Target
$2.00
IPSC Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Century Therapeutics, Inc. in the past 3 months
EPS Estimates — IPSC
68%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.61
vs Est –$1.62
▲ 0.4% off
2025
Actual –$0.11
vs Est –$0.18
▲ 63.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IPSC
74%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.007B
vs Est $0.003B
▲ 51.6% off
2025
Actual $0.109B
vs Est $0.109B
▼ 0.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
